Rome Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $72M
Overview
A biotech unlocking the therapeutic potential of the 'dark genome' to treat cancer and autoimmune diseases.
OncologyImmunologyAutoimmune Diseases
Technology Platform
A proprietary platform that uses computational and experimental tools to decode the 'dark genome' and identify novel, disease-driving repetitive elements as therapeutic targets.
Funding History
1Total raised:$72M
Series B$72M
Opportunities
Opportunity to develop first-in-class medicines for major diseases by targeting a vast and unexplored area of human biology.
Risk Factors
High biological risk that targets from the dark genome may not be druggable or may not translate to clinical efficacy in humans.
Competitive Landscape
Occupies a unique niche by targeting the dark genome, with limited direct competition but competing broadly with all companies in autoimmune disease and oncology drug development.